Hirslanden Klinik Hirslanden — Oncology, Zurich

Klinik Hirslanden is a private hospital in Zurich belonging to the Hirslanden hospital group. The oncology profile concerns cancer services within that hospital context, rather than a separate standalone cancer institution. Patients should distinguish the Zurich hospital from other Hirslanden locations when requesting appointments or reviewing available services.

The information supplied does not establish when the oncology service was founded or provide a verified measure of its size. Hospital-wide bed numbers, annual cancer caseloads and disease-specific treatment volumes are therefore not stated here. Patients seeking experience with an uncommon tumour or complex operation can ask for relevant team-level information.

The described service model emphasises personalised care with senior consultants, international patient coordination and prompt appointment scheduling. These are organisational features, not evidence of superior outcomes. Confirm who will oversee treatment, how specialists contribute to decisions and whether all proposed care will take place at the Zurich hospital.

Breast and prostate cancers are listed specialties. Depending on stage and tumour characteristics, care may involve surgery, radiation therapy, systemic medicines or surveillance. Patients should ask which disease-specific assessments are available and whether recommendations will be reviewed by specialists from the relevant disciplines. The supplied information does not establish comparative strength or outcome advantages for either programme.

Colorectal and lung cancers are also within the stated scope. Treatment planning generally requires accurate staging, pathology review and, for some diagnoses, molecular testing. These assessments help determine whether local treatment, drug treatment or a combined approach is appropriate.

Blood cancers are included, but this is a broad category covering leukaemias, lymphomas and myeloma. Confirm expertise in the exact diagnosis and availability of the proposed therapy. Stem-cell transplantation and cellular therapies should not be assumed to be available from this listing alone.

Surgery is among the listed treatment options. Its role depends on whether a tumour is operable, the aim of treatment and the patient's general health. Ask which surgical team would perform the procedure, where it would take place and what recovery and rehabilitation would involve.

Radiation therapy is also listed. It may be used alone, alongside medicines or before or after surgery. The appropriate technique and number of visits depend on the cancer and treatment goal; specific equipment or techniques are not established by this profile. Confirm the delivery site and schedule before arranging accommodation.

Systemic treatment options include chemotherapy, immunotherapy and targeted therapy. These medicines have different indications and side effects, and not every option is suitable for every cancer. Eligibility can depend on pathology, biomarkers, previous treatment, organ function and Swiss authorisation or funding arrangements.

Precision oncology uses tumour characteristics, including molecular findings where relevant, to inform treatment selection. Testing does not guarantee that a suitable targeted medicine or trial will be available. Ask whether further testing could change the recommendation, how uncertain findings are interpreted and whether testing costs are included in the estimate.

The supplied profile cites around 40 active oncology clinical trials. This figure is indicative and should not be treated as a live list of recruiting studies. Trials may be open, temporarily paused, closed to enrolment or continuing follow-up only. The information provided does not specify trial phases, cancer types or whether the count includes studies at other locations.

International patients should request a current study match through the treating team. Screening commonly considers the exact diagnosis, stage, biomarkers, previous therapies and general health. A records review may identify possibilities, but acceptance requires formal assessment and informed consent. Ask for the trial registration identifier, study location, visit schedule, language requirements and responsibility for routine-care and travel costs. Participation does not guarantee benefit.

Before booking travel, contact the international patient office through the official website and request instructions for submitting records securely. Explain whether you seek a second opinion, a procedure or a complete treatment course. Ask whether an initial review can take place remotely and obtain confirmation that the relevant specialty can assess your case. Do not delay urgent care while awaiting an overseas appointment.

Plan beyond the first consultation. Establish the likely time abroad, who manages complications and whether medicines or follow-up tests can be arranged at home. Request a written estimate and clarify insurer approval, deposits and exclusions. Your current clinician and the Zurich team should agree how records, treatment summaries and urgent concerns will be communicated.

Contact details below come from the hospital's own published international patient information.

Location: Zurich, Switzerland

Email: No public international e-mail address is published; use the website enquiry form.

Phone: +41 44 387 21 11

Website: https://www.hirslanden.ch

Languages supported: German, English, French, Italian, Arabic, Russian

Remote second opinion: Available

Always confirm current contact details on the hospital's own website before sending medical records, and never send documents to an address you have not verified.